Market research reports tell you the aggregate picture: medical devices in Southeast Asia are growing at 8–12% annually, driven by rising incomes, aging populations, and expanding healthcare infrastructure. What they don't give you is the category-level view — which specific device types are seeing registration activity pick up, and where.
Registration data is a leading indicator of commercial activity. Companies register devices before they sell them. When a new wave of registrations appears in a category across multiple markets in a short window, it signals that multiple manufacturers believe demand in that category is growing. The registration wave typically precedes the revenue wave by 12–24 months.
Here's what the data shows for the major device categories across our eight indexed Asian markets.
In vitro diagnostics (IVD): the post-pandemic acceleration that didn't stop
IVD — in vitro diagnostic devices, which includes everything from blood glucose tests to molecular diagnostic platforms — saw an enormous registration spike during 2020–2022 driven by COVID-19 test kit registrations. What's interesting is what happened after: IVD registration activity didn't return to pre-pandemic baseline levels. It settled at a higher plateau.
The explanation is structural. The pandemic created regulatory infrastructure (expedited review pathways, expanded laboratory capacity) and consumer familiarity with at-home diagnostics that persisted. Markets that had minimal IVD registration activity before 2020 — particularly Vietnam and Indonesia — now show sustained registration activity in molecular diagnostics, point-of-care testing, and immunoassay platforms.
Indonesia is particularly notable: BPOM IVD registrations have grown significantly, with new entrants from Chinese IVD manufacturers — domestic to China but newly expanding internationally — alongside the established multinational players. This represents a meaningful shift in the competitive landscape.
Diagnostic imaging: steady growth with a Japan concentration
Diagnostic imaging — ultrasound, X-ray, CT, MRI — shows sustained registration growth across the region, with Japan remaining the dominant market by registration volume. Japan's PMDA database contains more diagnostic imaging registrations than any other market in our index, reflecting both the size of Japan's radiology infrastructure and the maturity of the market for imaging upgrades.
In Southeast Asia, ultrasound registrations have grown particularly strongly in Indonesia, Thailand, and Vietnam — driven by both hospital infrastructure expansion and the growth of private clinics and maternal health facilities that use ultrasound as a primary diagnostic tool. Point-of-care ultrasound devices (POCUS) have registered in markets where traditional diagnostic imaging was too expensive for widespread deployment.
Singapore remains the regional registration hub for high-end imaging systems — MRI, advanced CT — before those products are progressively registered in other markets. Watching Singapore HSA registrations is often a leading indicator of what will appear in BPOM or MDA 12–18 months later.
Cardiac devices: high-risk, high-value, Singapore-led
Cardiac devices — coronary stents, cardiac rhythm management (pacemakers, ICD, CRT), structural heart — show a distinctive pattern in the registration data. New product registrations consistently appear in Singapore first. HSA's rigorous but efficient review process and Singapore's role as a regional medical hub makes it the natural first-market in the region for high-risk cardiovascular devices.
Malaysia and Thailand follow, typically 12–24 months after Singapore. Indonesia tends to see registrations of established cardiac devices rather than first-in-class products, reflecting both the complexity of BPOM's Class D review and the economics of Indonesia's hospital procurement system.
Japan has the largest absolute cardiac device registration count in our database, and the PMDA approval list includes many cardiac technologies not yet registered elsewhere in Asia — a useful benchmark for what's coming.
Orthopedics and joint replacement: an aging population story
Orthopedic registrations — hip replacements, knee implants, spine fixation systems — are growing across all markets, but the growth pattern differs by market segment. Japan's PMDA database reflects the world's most rapidly aging population: it has the highest density of orthopedic registrations per capita in our index, with both global multinationals and Japanese domestic manufacturers active in the category.
In Southeast Asia, private hospital growth is the driver. As Thailand, Malaysia, and Singapore's private hospital sectors expand capacity and attract medical tourists, orthopedic procedure volumes have grown faster than the domestic population aging curve would suggest. Medical tourism for orthopedics — particularly joint replacement — is well-established in Thailand and Malaysia, pulling forward device demand.
Explore registration data for your device category
Search by device type across 8 Asian markets. See who's registered, what classes they've filed in, and how competitive activity has changed. 50 free searches per month.
Start searching free →Wound care: the Class B Indonesia opportunity
Wound care products — dressings, wound management systems, negative pressure wound therapy — show interesting registration patterns in Indonesia specifically. BPOM's Class B category (medium-low risk) contains a large number of wound care products, and the registration data shows a steady increase in new product introductions by both global brands and regional manufacturers.
The Indonesia wound care opportunity reflects several converging factors: a large diabetic population driving chronic wound management demand, expansion of community healthcare facilities that need primary wound care products, and an increasingly sophisticated private hospital sector with purchasing power for advanced wound therapies.
The Class B wound care registration path in Indonesia, while not trivial, is more manageable than Class C/D, which makes it accessible to mid-sized manufacturers that might not have the resources for a full Class C registration campaign simultaneously.
What registration data doesn't show — and what to do about it
Registration data is a leading indicator, not a complete market picture. A high volume of registrations in a category doesn't guarantee that all those products are commercially successful — some registrations are defensive (preventing competitors from holding the registration) or aspirational (registered before distribution is secured). A low volume of registrations doesn't mean the category is small — it may mean devices are being sold through gray-market channels or under older registration numbers.
The most useful approach is to combine registration data with sales data where available (distributor reports, market research) and clinical adoption data (published study counts, conference presentations). Registration data tells you who's trying to be in the market; sales data tells you who's succeeding.
Markets to watch
Vietnam's registration activity across multiple categories has accelerated in the past two years, consistent with its GDP growth and healthcare investment trajectory. Vietnam is currently underpenetrated relative to its population for most device categories, and the reference country fast-track pathway makes it accessible for companies with FDA or CE approvals.
Indonesia remains the largest prize by population but requires the most sustained regulatory investment. The companies that have built Indonesia registration pipelines — not just one-off registrations but systematic coverage of their product portfolio — are positioned to benefit as Indonesia's middle class continues to expand its healthcare utilization.